Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quality of life, survival, comorbidities, and pharmacoeconomics in elderly AML patients treated with HMA combination regimens
NL-OMON53259Recruiting
- Sponsor
- Medisch Centrum Leeuwarden
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of azacitidine, decitabine, venetoclax and ivosidenib in acute myeloid leukemia (AML), sponsored by Medisch Centrum Leeuwarden. Primary endpoint: Quality of life over time. Started Oct 2023; status: recruiting.
02
Drugs
azacitidinedecitabinevenetoclaxivosidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON53259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53259.